---
title: Study of Virus-specific Lymphocytic Cell Populations in Non-invasive Nasal Mucosa Samples of MIS-C Patients
nct_id: NCT05560906
overall_status: UNKNOWN
sponsor: Medical University of Warsaw
study_type: OBSERVATIONAL
primary_condition: MIS-C Associated With COVID-19
countries: Poland
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05560906.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05560906"
ct_last_update_post_date: 2022-09-30
last_seen_at: "2026-05-12T06:40:41.984Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Study of Virus-specific Lymphocytic Cell Populations in Non-invasive Nasal Mucosa Samples of MIS-C Patients

**Official Title:** Study of Virus-specific Lymphocytic Cell Populations in Non-invasive Nasal Mucosa Samples of MIS-C Patients, and Intra-population Shifts in Inflammatory Tissues in the Acute Phase of MIS-C and in Health

**NCT ID:** [NCT05560906](https://clinicaltrials.gov/study/NCT05560906)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 20
- **Lead Sponsor:** Medical University of Warsaw
- **Collaborators:** Erasmus Medical Center, Leiden University Medical Center
- **Conditions:** MIS-C Associated With COVID-19, COVID-19
- **Start Date:** 2021-12-06
- **Completion Date:** 2022-12
- **CT.gov Last Update:** 2022-09-30

## Brief Summary

The aim of the study is to make an accurate assessment of immune cells obtained from nasal mucosa and peripherial blood of MIS-C patients during the disease and the period of health.

## Detailed Description

The study will consist of two parts. Initially, it will be of a cross-cutting comparative nature, when a group of healthy patients (control group) and a group of patients diagnosed with MIS-C/PIMS syndrome are compared with each other, based on nasal curettage swabs and peripheral blood, before the inclusion of systemic anti-inflammatory treatment (study group). In addition, an observation of the research group will be carried out, during which swabs and peripheral blood will be taken at two more control points.

## Eligibility

- **Maximum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* MIS-C diagnosis based of WHO diagnostic criteria.

Exclusion Criteria:

* immunosuppressive treatment received up to 3 months before
* intranasal drugs received up to 7 days before
* COVID-19 vaccination
* no consent
```

## Arms

- **Control group** — Healthy patients under 18 years of age.
- **MIS-C group** — Patients with MIS-C diagnosed, based on WHO diagnostic criteria.

## Primary Outcomes

- **Change in leukocyte subpopulations in nasal mucosa and peripherial blood during MIS-C and convalescence.** _(time frame: Three clinical timepoints: (i) baseline (preferably before immunomodulatory treatment), (ii) convalescence, after major symptoms resolution (1 week +/-2 days after treatment introduction), (iii) outpatient control visit (6 weeks after hospital discharge))_ — The cellular subpopulations will be characterized and clustered using prepared immunomarker array.

## Locations (1)

- Pediatric teaching clinical hospital, Warsaw Medical University, Warsaw, Masovian Voivodeship, Poland — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.pediatric teaching clinical hospital, warsaw medical university|warsaw|masovian voivodeship|poland` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05560906.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05560906*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*